1910 Genetics

20n Bio

3DBio Therapeutics is implanting 3D-bioprinted living tissues in patients. Living tissue implants are regenerative medicines that can be built from a patient’s own healthy tissue. 3DBio is generating personalized tissue implants using their four-part technology platform including their proprietary 3D-bioprinter (GMPrint), bio-ink (ColVivo), specialized cell culture and implantable protective shells. These implants are patient-matched and patient-derived, and 3DBio’s first product, AuriNovo, is being tested in clinical trials in adults and children. AuriNovi is created from a small biopsy on the patient’s ear remnant which is then used by 3DBio to print new, normally-shaped ears. The newly created ear is implanted into the patient clinically.

3DBio Therapeutics is implanting 3D-bioprinted living tissues in patients. Living tissue implants are regenerative medicines that can be built from a patient’s own healthy tissue. 3DBio is generating personalized tissue implants using their four-part technology platform including their proprietary 3D-bioprinter (GMPrint), bio-ink (ColVivo), specialized cell culture and implantable protective shells. These implants are patient-matched and patient-derived, and 3DBio’s first product, AuriNovo, is being tested in clinical trials in adults and children. AuriNovi is created from a small biopsy on the patient’s ear remnant which is then used by 3DBio to print new, normally-shaped ears. The newly created ear is implanted into the patient clinically.

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio is discovering new mammalian cell lines to transform cell and gene therapy manufacturing. To develop and manufacture cell therapies, cell lines that are easy to manipulate, engineer and grow are required. 64x Bio is using their VectorSelect platform to generate highly optimized cell lines that meet the requirements for production of cell therapies. In particular, 64x Bio is enhancing the efficiency of cell lines to manufacture viral vectors that improve manufacturing capacity and reduce overall cost. This involves high-throughput genome engineering, screening technologies and 64x Bio’s proprietary genetic barcoding method that connects information of viral vector productivity back to the parent cell which produced it.

64x Bio is discovering new mammalian cell lines to transform cell and gene therapy manufacturing. To develop and manufacture cell therapies, cell lines that are easy to manipulate, engineer and grow are required. 64x Bio is using their VectorSelect platform to generate highly optimized cell lines that meet the requirements for production of cell therapies. In particular, 64x Bio is enhancing the efficiency of cell lines to manufacture viral vectors that improve manufacturing capacity and reduce overall cost. This involves high-throughput genome engineering, screening technologies and 64x Bio’s proprietary genetic barcoding method that connects information of viral vector productivity back to the parent cell which produced it.

64x Bio

8Biomed

A-Alpha Bio is accelerating drug discovery by providing cell-based tools of protein interactions. Protein interactions govern all cellular processes and are therefore linked with disease.  However, while predictive tools are now available for an individual protein structure, understanding protein interactions requires time-consuming experimentation. A-Alpha is circumventing this by generating high-quality protein-protein interaction data by measuring millions of protein-protein interactions at a time using AlphaSeq. AlphaSeq combines yeast two-hybrid technology with DNA barcodes to read out high-affinity interactions. This approach can be used to discover effective antibodies and degradable neo-substrates, engineer protein interfaces, and fuel predictive machine learning models. 

A-Alpha Bio is accelerating drug discovery by providing cell-based tools of protein interactions. Protein interactions govern all cellular processes and are therefore linked with disease. However, while predictive tools are now available for an individual protein structure, understanding protein interactions requires time-consuming experimentation. A-Alpha is circumventing this by generating high-quality protein-protein interaction data by measuring millions of protein-protein interactions at a time using AlphaSeq. AlphaSeq combines yeast two-hybrid technology with DNA barcodes to read out high-affinity interactions. This approach can be used to discover effective antibodies and degradable neo-substrates, engineer protein interfaces, and fuel predictive machine learning models.

A-Alpha Bio

A2 Biotherapeutics

AavantiBio

AB Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Absci

Accelevir Diagnostics

Accent Therapeutics

ACELYRIN

Acepodia

Achieve Life Sciences

Acrivon Therapeutics

Acrotech Biopharma

Acutis Diagnostics

Adagio Therapeutics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

adMare BioInnovations

Admera Health

Adverum Biotechnologies

adyn

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax is developing a next-generation approach in vaccine technologies. The Centers for Disease Control and Prevention estimates that 4% of patients will contract a healthcare-associated infection each year due to antimicrobial resistance. Affinivax is addressing antimicrobial resistance with their patented technology platform called the Multiple Antigen Presentation System (MAPSTM) to develop several vaccines. The MAPSTM platform simplifies vaccine design and selects for key immunogenic epitopes to induce robust immune protection in a single vaccine.

The novel vaccines designed by Affinivax are to be tested against challenging infectious diseases. AFX3772, their lead vaccine candidate for Streptococcus pneumoniae, is expected to be tested in Phase 3 clinical trials this year.

Affinivax is developing a next-generation approach in vaccine technologies. The Centers for Disease Control and Prevention estimates that 4% of patients will contract a healthcare-associated infection each year due to antimicrobial resistance. Affinivax is addressing antimicrobial resistance with their patented technology platform called the Multiple Antigen Presentation System (MAPSTM) to develop several vaccines. The MAPSTM platform simplifies vaccine design and selects for key immunogenic epitopes to induce robust immune protection in a single vaccine.
The novel vaccines designed by Affinivax are to be tested against challenging infectious diseases. AFX3772, their lead vaccine candidate for Streptococcus pneumoniae, is expected to be tested in Phase 3 clinical trials this year.

Affinivax

AgBiome

Agena Bioscience

AiLife Diagnostics

Akero Therapeutics

Akouos is developing AAV-based gene therapies to treat hearing loss that results from mutations in genes for inner ear function. Akouos uses specialized vectors and surgical procedures to target the inner ear.

Akouos has exclusive rights to AAV vectors that were designed specifically for diseases of the inner ear, hearing, and balance. For example, the company uses a vector called Anc8OL65 that transduces sensory cells and cochlear cells with high efficiency. Akouos delivers their gene therapies via minimally invasive surgery along the sensory epithelium, where target cells of the inner ear are located. The therapies work by various mechanisms, including delivery of a healthy gene in loss-of-function mutations, delivery of RNAi, and delivery of a protein that alters a disease pathway.

Akouos is developing AAV-based gene therapies to treat hearing loss that results from mutations in genes for inner ear function. Akouos uses specialized vectors and surgical procedures to target the inner ear.
Akouos has exclusive rights to AAV vectors that were designed specifically for diseases of the inner ear, hearing, and balance. For example, the company uses a vector called Anc8OL65 that transduces sensory cells and cochlear cells with high efficiency. Akouos delivers their gene therapies via minimally invasive surgery along the sensory epithelium, where target cells of the inner ear are located. The therapies work by various mechanisms, including delivery of a healthy gene in loss-of-function mutations, delivery of RNAi, and delivery of a protein that alters a disease pathway.

Akouos

Alamar Biosciences

Alector is developing therapies for the treatment of neurodegenerative diseases. Despite the rise in the number of patients suffering with brain disorders there is still a lack of effective therapeutics. Immune cells in the brain are important for brain health. By combining antibody technology, human genetics and the latest insights in neuroscience, Alector is building a pipeline of therapeutics to harness the body’s own immune system to heal itself. This immuno-neurology strategy is analogous to current immuno-oncology approaches to activate and recruit the adaptive immune response. Through partnering with other companies such as GSK, Alector currently has many therapeutics in Phase 1-3 clinical trials for dementia and Alzheimer’s disease.

Alector is developing therapies for the treatment of neurodegenerative diseases. Despite the rise in the number of patients suffering with brain disorders there is still a lack of effective therapeutics. Immune cells in the brain are important for brain health. By combining antibody technology, human genetics and the latest insights in neuroscience, Alector is building a pipeline of therapeutics to harness the body’s own immune system to heal itself. This immuno-neurology strategy is analogous to current immuno-oncology approaches to activate and recruit the adaptive immune response. Through partnering with other companies such as GSK, Alector currently has many therapeutics in Phase 1-3 clinical trials for dementia and Alzheimer’s disease.

Alector

Aleo BME

AlivaMab Discovery Services

Alkahest is developing treatments for neurodegenerative and age-related diseases. Many proteins that increase or decrease with age can be identified in the blood plasma. Alkahest is characterizing these proteins, known as chronokines, to create therapeutics to slow down or reverse age-related diseases. In particular, Alkahest is interested in chronokines involved in promoting restorative biological processes or pathological degenerative processes as therapeutic targets. Target identification follows the traditional pharmaceutical method, supplemented with Alkahest’s highly selected and refined plasma fractions. Using this approach, Alkahest has many product candidates in Phase 1 & 2 clinical trials.

Alkahest is developing treatments for neurodegenerative and age-related diseases. Many proteins that increase or decrease with age can be identified in the blood plasma. Alkahest is characterizing these proteins, known as chronokines, to create therapeutics to slow down or reverse age-related diseases. In particular, Alkahest is interested in chronokines involved in promoting restorative biological processes or pathological degenerative processes as therapeutic targets. Target identification follows the traditional pharmaceutical method, supplemented with Alkahest’s highly selected and refined plasma fractions. Using this approach, Alkahest has many product candidates in Phase 1 &amp; 2 clinical trials.

Alkahest

Alladapt Immunotherapeutics

Allakos is developing antibody-based therapeutics to treat allergic and inflammatory diseases. Eosinophils and mast cells, both types of immune cells, play a role in pathogenesis of many acute and chronic inflammatory diseases. Allakos is targeting receptors expressed on the surface of different immune cells with therapeutic antibodies. Allakos’ lead therapeutic target, AK002, binds a receptor on eosinophils to deplete them as they are elevated in patients with eosinophilic gastrointestinal diseases. The receptor is Siglec-8, which when activated by the antibody, induces apoptosis in eosinophils. Positive clinical activity of AK002 has already been seen and Allokos is continuing to test the drug in more eosinophil-driven diseases.

Allakos is developing antibody-based therapeutics to treat allergic and inflammatory diseases. Eosinophils and mast cells, both types of immune cells, play a role in pathogenesis of many acute and chronic inflammatory diseases. Allakos is targeting receptors expressed on the surface of different immune cells with therapeutic antibodies. Allakos’ lead therapeutic target, AK002, binds a receptor on eosinophils to deplete them as they are elevated in patients with eosinophilic gastrointestinal diseases. The receptor is Siglec-8, which when activated by the antibody, induces apoptosis in eosinophils. Positive clinical activity of AK002 has already been seen and Allokos is continuing to test the drug in more eosinophil-driven diseases.

Company, website	Founded	Location	Size	Funding
1. 1910 Genetics	2018	Boston, MA	1-50	10-100M
2. 20n Bio	2021	Philadelphia, PA	1-50	<10M
3. 3DBio Therapeutics	2014	Long Island City, NY	1-50	<10M
4. 3T Biosciences	2017	San Francisco, CA	1-50	10-100M
5. 4D Molecular Therapeutics	2013	Emeryville, CA	101-250	100-500M
6. 64x Bio	2018	San Francisco, CA	1-50	10-100M
7. 8Biomed	2018	Malvern, PA	1-50	not disclosed
8. A-Alpha Bio	2017	Seattle, WA	1-50	10-100M
9. A2 Biotherapeutics	2018	Agoura Hills, CA	51-100	100-500M
10. AavantiBio	2019	Cambridge, MA	1-50	100-500M
11. AB Studio	2017	Hayward, CA	1-50	not disclosed
12. Abalone Bio	2017	Emeryville, CA	1-50	<10M
13. Abata Therapeutics	2021	Cambridge, MA	1-50	10-100M
14. Abeona Therapeutics	2015	New York, NY	51-100	100-500M
15. Abintus Bio	2020	San Diego, CA	1-50	not disclosed
16. Absci	2011	Vancouver, WA	101-250	100-500M
17. Accelevir Diagnostics	2015	Baltimore, MD	1-50	<10M
18. Accent Therapeutics	2017	Lexington, MA	1-50	100-500M
19. ACELYRIN	2020	Los Angeles, CA	1-50	100-500M
20. Acepodia	2016	Alameda, CA	1-50	100-500M
21. Achieve Life Sciences	2015	Seattle, WA	1-50	10-100M
22. Acrivon Therapeutics	2018	Cambridge, MA	1-50	100-500M
23. Acrotech Biopharma	2018	East Windsor, NJ	51-100	not disclosed
24. Acutis Diagnostics	2014	Hicksville, NY	101-250	no disclosed
25. Adagio Therapeutics	2020	Waltham, MA	51-100	100-500M
26. Adaptive Phage Therapeutics	2016	Gaithersburg, MD	1-50	10-100M
27. Adcentrx Therapeutics	2021	San Diego, CA	1-50	10-100M
28. Adicet Bio	2014	Menlo Park, CA	51-100	100-500M
29. adMare BioInnovations	2019	Vancouver, BC	101-250	10-100M
30. Admera Health	2014	South Plainfield, NJ	51-100	not disclosed
31. Adverum Biotechnologies	2012	Redwood City, CA	101-250	100-500M
32. adyn	2020	Seattle, WA	1-50	<10M
33. Aeglea BioTherapeutics	2013	Austin, TX	101-250	10-100M
34. Aether Bio	2017	Menlo Park, CA	1-50	not disclosed
35. Affini-T Therapeutics	2021	Watertown, MA	1-50	not disclosed
36. Affinia Therapeutics	2019	Waltham, MA	51-100	100-500M
37. Affinivax	2014	Cambridge, MA	101-250	100-500M
38. AgBiome	2012	Research Triangle Park, NC	101-250	100-500M
39. Agena Bioscience	2014	San Diego, CA	101-250	not disclosed
40. AiLife Diagnostics	2018	Pearland, TX	1-50	not disclosed
41. Akero Therapeutics	2017	San Francisco, CA	1-50	100-500M
42. Akouos	2016	Boston, MA	51-100	100-500M
43. Alamar Biosciences	2018	Fremont, CA	1-50	10-100M
44. Alector	2013	San Francisco, CA	101-250	100-500M
45. Aleo BME	2015	State College, PA	1-50	10-100M
46. AlivaMab Discovery Services	2018	San Diego, CA	1-50	not disclosed
47. Alkahest	2014	San Carlos, CA	51-100	10-100M
48. Alladapt Immunotherapeutics	2018	Menlo Park, CA	1-50	10-100M
49. Allakos	2012	Redwood City, CA	101-250	100-500M
50. Allarta Life Science	2018	Hamilton, ON	1-50	<10M

Companies